Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 19.46 USD -0.61% Market Closed
Market Cap: 120m USD
Have any thoughts about
Aligos Therapeutics Inc?
Write Note

Aligos Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aligos Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Aligos Therapeutics Inc
NASDAQ:ALGS
Cash Equivalents
$135.7m
CAGR 3-Years
-15%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%

See Also

What is Aligos Therapeutics Inc's Cash Equivalents?
Cash Equivalents
135.7m USD

Based on the financial report for Dec 31, 2023, Aligos Therapeutics Inc's Cash Equivalents amounts to 135.7m USD.

What is Aligos Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
41%

Over the last year, the Cash Equivalents growth was 67%. The average annual Cash Equivalents growth rates for Aligos Therapeutics Inc have been -15% over the past three years , 41% over the past five years .

Back to Top